Benefits and Risks of Antipsychotic Polypharmacy: An Evidence-Based Review of the Literature

ISSN： 0114-5916

Source： Drug Safety, Vol.31, Iss.1, 2008-01, pp. : 7-20

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antipsychotic Polypharmacy in Schizophrenia: Benefits and Risks

By Barnes Thomas R.E. Paton Carol

CNS Drugs, Vol. 25, Iss. 5, 2011-05 ,pp. : 383-399

Adis International

Access to resources Recommend Favorite

Antipsychotic Polypharmacy

Current Pharmaceutical Design, Vol. 10, Iss. 18, 2004-07 ,pp. : 2231-2238

Bentham Science Publishers

Access to resources Recommend Favorite

Antipsychotic Polypharmacy: Still Dirty, But Hardly a Secret. A Systematic Review and Clinical Guide

By K. Tracy Derek Sendt Kyra-Verena S. Shergill Sukhwinder

Current Psychopharmacology, Vol. 2, Iss. 2, 2013-05 ,pp. : 143-171

Bentham Science Publishers

Access to resources Recommend Favorite

A Critical Review of Atypical Antipsychotic Utilization: Comparing Monotherapy with Polypharmacy and Augmentation

Current Medicinal Chemistry, Vol. 11, Iss. 3, 2004-02 ,pp. : 313-327

Bentham Science Publishers

Access to resources Recommend Favorite

Safety and tolerability of antipsychotic polypharmacy

By Gallego Juan A Nielsen Jimmi De Hert Marc Kane John M Correll Christoph U

Expert Opinion on Drug Safety, Vol. 11, Iss. 4, 2012-07 ,pp. : 527-542

Informa Healthcare

Access to resources Recommend Favorite